Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy

Transplant Infectious Disease

Volumn 12, Issue 4, 2010, Pages 322-329

  George, B ^a   Pati, N ^a   Gilroy, N ^a   Ratnamohan, M ^a   Huang, G ^a   Kerridge, I ^a   Hertzberg, M ^a   Gottlieb, D ^a   Bradstock, K ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

CMV; HSCT; reactivation; seropositive recipient

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; ETANERCEPT; GAMMAGARD SD; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; T CELL DEPLETION; UMBILICAL CORD BLOOD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 77955942421     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00504.x     Document Type: Article

References (25)

1. Osarogiagbon RU, Defor TE, Weisdorf MA, et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 2000 6 (3) : 280 288.
2. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008 42 (Suppl 1) : S70 S72.
3. Hebart H, Jahn G, Sinzger C, et al. CMV infection in bone marrow and solid organ transplant patients in the era of antiviral prophylaxis. Herpes 2001 7 (1) : 13 17.
4. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002 35 : 999 1004.
5. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996 88 : 4063 4071.
6. Rubie H, Attal M, Campardou AM, et al. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993 11 (3) : 209 214.
7. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992 77 (6) : 507 513.
8. Atkinson K, Arthur C, Bradstock K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995 16 (3) : 401 405.
9. Boeckh M, Nichols G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004 103 (6) : 2003 2008.
10. Nichols WG, Corey L, Gooley T. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002 185 : 273 282.
11. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000 95 : 2219 2225.
12. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986 67 : 1162 1167.
13. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006 91 (1) : 78 83.
14. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002 99 (6) : 1978 1985.
15. Schetelig J, Oswald O, Steuer N, et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003 32 (7) : 695 701.
16. Hill QA, Hill A, Collyns TA, et al. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008 41 (8) : 749 751.
17. Nachbaur D, Larcher C, Kircher B, et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003 82 (10) : 621 627.
18. Chae YS, Sohn SK, Kim JG, et al. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008 83 (8) : 649 653.
19. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002 99 (12) : 4357 4363.
20. Hambach L, Stadler M, Dammann E, et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002 29 (11) : 903 906.
21. Junghanss C, Storb R, Maris MB, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003 123 (4) : 662 670.
22. Walker CM, van Burik JA, De For TE, et al. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007 13 (9) : 1106 1115.
23. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose-ranging study. Blood 2008 111 (11) : 5403 5410.
24. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007 13 (6) : 707 714.
25. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008 112 (10) : 3974 3981.